The COVID-19 Ontario Pregnancy Event (COPE) Network: Assessing the impact of COVID-19 in pregnancy on maternal, fetal and newborn health [Added supplement: COVID-19 Variant Supplement]

  • Funded by Canadian Institutes of Health Research (CIHR)
  • Total publications:0 publications

Grant number: 172760, 175557

Grant search

Key facts

  • Disease

    COVID-19
  • Start & end year

    2020
    2022
  • Known Financial Commitments (USD)

    $625,031.42
  • Funder

    Canadian Institutes of Health Research (CIHR)
  • Principle Investigator

    Pending
  • Research Location

    Canada, Americas
  • Lead Research Institution

    Ottawa Hospital Research Institute Clinical Epidemiology
  • Research Category

    Pathogen: natural history, transmission and diagnostics

  • Research Subcategory

    Pathogen morphology, shedding & natural history

  • Special Interest Tags

    Gender

  • Study Subject

    Clinical

  • Clinical Trial Details

    Not applicable

  • Broad Policy Alignment

    Pending

  • Age Group

    Adults (18 and older)Newborns (birth to 1 month)

  • Vulnerable Population

    Pregnant womenOther

  • Occupations of Interest

    Unspecified

Abstract

In order to assess the mother-to-infant and potential vertical transmission of SARS-CoV-2 infection in pregnant women, maternal and neonatal biological samples will be prospectively collected from women with confirmed or suspected COVID-19 at participating hospitals across Ontario. Samples will be tested for the SARS-CoV-2 serology and viral load. The study population will consist of pregnant women with confirmed or suspected COVID-19 at any point during pregnancy, who will be delivering at a participating hospital within Ontario and agree to provide maternal and/or neonatal samples. Outcomes for the study objective will be ascertained through the collection and testing of biological samples from the mother and/or infant. Specifically we will: 1) Assess vaginal mucosa, amniotic fluid, placenta, breastmilk, cord blood and neonatal nasopharyngeal swab for RNA particles of SARS-CoV-2, by ddPCR. 2) Examine the impact of SARS-CoV-2 impact on neonate with respect to serology and viral load, in addition to placenta pathology findings and ddPCR. 3) Assess vertical transmission and the effect of SARS-CoV-2 through placental pathology examina